Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 13 of 13 entries
View as:

Study Evaluating the Safety of Intranasal Administration of 400 μg of Fluticasone Propionate Twice a Day (BID) Using a Novel Bi-Directional Device in Subjects With Chronic Sinusitis With or Without Nasal Polyps

Phase: N/A Priority: Normal
NCT ID: NCT01623323 Org: User:
Start: 09/30/13 End: 03/31/15 Due: 03/31/16

A Study to Compare the Bioavailability Intranasal Administration of 200 and 400 µg or 400 µg Alone of OPTINOSE™ FLUTICASONE With 440 µg of Flovent® HFA (Fluticasone Propionate) Inhalation Aerosol (Part 2)

Phase: N/A Priority: Normal
NCT ID: NCT02266927 Org: User:
Start: 09/30/14 End: 04/30/15 Due: 04/30/16

12-Month OL Intranasal Fluticasone Propionate BID Using OptiNose Device

Phase: N/A Priority: Normal
NCT ID: NCT01623310 Org: User:
Start: 09/30/13 End: 10/31/15 Due: 10/31/16

Efficacy and Safety Study of Intranasal Administration of 100, 200, and 400 μg of Fluticasone Propionate Using a Novel Bi-directional Device

Phase: N/A Priority: Normal
NCT ID: NCT01624662 Org: User:
Start: 10/30/13 End: 07/03/15 Due: 07/03/16

Bioavailability Study to Compare OPTINOSE SUMATRIPTAN With IMITREX® in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT01507610 Org: User:
Start: 01/31/12 End: 02/29/12 Due: 02/28/13

Efficacy & Safety of OPN-375 Adults With Bilateral Nasal Polyps Using Nasoendoscopic Video

Phase: N/A Priority: Normal
NCT ID: NCT03591068 Org: User:
Start: 06/07/18 End: 02/22/19 Due: 02/22/20

Study Evaluating the Efficacy and Safety of Intranasal Administration of 100, 200, and 400 μg of Fluticasone Propionate Twice a Day (BID) Using a Novel Bi Directional Device in Subjects With Bilateral Nasal Polyposis Followed by an 8-Week Open-Label Extension Phase to Assess Safety

Phase: N/A Priority: Normal
NCT ID: NCT01622569 Org: User:
Start: 11/19/13 End: 10/01/15 Due: 10/01/16

Efficacy and Safety of 186 mcg of OPN-375 Nasal Spray Twice a Day (BID) in Adolescents With Chronic Rhinosinusitis Without Nasal Polyps

Phase: N/A Priority: Normal
NCT ID: NCT06850805 Org: User:
Start: 07/30/25 End: 10/31/28 Due: 10/31/29

OPN-375 Efficacy and Safety in Adolescents With Bilateral Nasal Polyps

Phase: N/A Priority: Normal
NCT ID: NCT03747458 Org: User:
Start: 12/31/18 End: 03/31/26 Due: 03/31/27

Study Evaluating the Efficacy and Safety of Intranasal Administration of OPN-375 in Subjects With Chronic Rhinosinusitis With or Without the Presence of Nasal Polyps

Phase: N/A Priority: Normal
NCT ID: NCT03781804 Org: User:
Start: 11/27/18 End: 01/19/22 Due: 01/19/23

Safety & Efficacy of a Single Dose of Sumatriptan Powder Delivered Intranasally With the Bi-directional Device in Adults With Acute Migraine

Phase: N/A Priority: Normal
NCT ID: NCT01462812 Org: User:
Start: 01/31/11 End: 06/30/12 Due: 06/30/13

Study Evaluating the Efficacy and Safety of Intranasal Administration of OPN-375 in Subjects With Chronic Rhinosinusitis Without the Presence of Nasal Polyps

Phase: N/A Priority: Normal
NCT ID: NCT03960580 Org: User:
Start: 06/06/19 End: 05/04/22 Due: 05/04/23

A Study to Evaluate Change in Viral Load After OPN-019 in Adults With COVID-19

Phase: N/A Priority: Normal
NCT ID: NCT05035576 Org: User:
Start: 09/01/21 End: 11/30/21 Due: 11/30/22